{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:21:29Z","timestamp":1790713289911,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report a case of a woman who continued erenumab for migraine prophylaxis throughout her pregnancy and to review the literature for pregnancy safety data for the calcitonin gene\u2010related peptide (CGRP) receptor and ligand\u2010directed therapies currently approved for migraine prophylaxis in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a common headache disorder that can be significantly disabling. Many people experiencing migraine seek out preventative therapies to improve their quality of life. Unfortunately, currently approved prophylactic agents may not be safe to use during pregnancy, potentially limiting the use of these agents in women of childbearing potential. As the newest class of prophylactic agents for migraine, CGRP agents have limited pregnancy safety data in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review of the literature was conducted through the PubMed database using the terms pregnancy and either erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, or atogepant. Additional sources of information such as prescribing information, assessment reports submitted to the European Medicines Agency (EMA), and manufacturer data were sought.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One case report was found in the literature documenting a human pregnancy with no adverse effects in the baby after exposure to erenumab. However, the last dose was administered in the second week of pregnancy and discontinued thereafter. The evaluation of 92\u00a0safety reports describing maternal exposure prior to or during pregnancy to either erenumab, galcanezumab, or fremanezumab was located. Incidence of miscarriage and congenital anomalies appear to be similar to rates in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of erenumab during pregnancy in our patient resulted in no known harm to the child. This case is unique in that the mother continued to receive erenumab throughout the pregnancy. Safety data is lacking regarding the use of these agents during pregnancy, despite their frequent use in women of childbearing potential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14305","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T05:30:03Z","timestamp":1650864603000},"page":"1256-1263","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review"],"prefix":"10.1111","volume":"62","author":[{"given":"Sierra J.","family":"Vig","sequence":"first","affiliation":[{"name":"Department of Pharmacy South Texas Veterans Health Care System  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Garza","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The University of Texas at Austin College of Pharmacy  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunting","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The University of Texas at Austin College of Pharmacy  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Depacon (Valproate Sodium) [package insert]","author":"AbbVie"},{"key":"e_1_2_9_3_1","volume-title":"FDA Drug Safety Communication: Valproate Anti\u2010seizure Products Contraindicated for Migraine Prevention in Pregnant Women Due to Decreased IQ Scores in Exposed Children","year":"2013"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190012442068"},{"key":"e_1_2_9_5_1","volume-title":"FDA Drug Safety Communication: Risk of Oral Clefts in Children Born to Mothers Taking Topamax (Topiramate)","year":"2011"},{"key":"e_1_2_9_6_1","volume-title":"Tegretol\u00ae (Carbamazepine) [package insert]","author":"Novartis Pharmaceuticals Corporation"},{"key":"e_1_2_9_7_1","volume-title":"Trileptal\u00ae (Oxcarbazepine) [package insert]","author":"Novartis Pharmaceuticals Corporation"},{"key":"e_1_2_9_8_1","volume-title":"Dilantin\u00ae (Phenytoin Sodium) [package insert]","author":"Pfizer, Inc."},{"key":"e_1_2_9_9_1","volume-title":"Amitriptyline Hydrochloride [package insert]","author":"Sandoz, Inc."},{"key":"e_1_2_9_10_1","volume-title":"Lopressor\u00ae (metoprolol tartrate) [package insert]","author":"Novartis Pharmaceuticals Corporation"},{"key":"e_1_2_9_11_1","volume-title":"Inderal\u00ae (Propranolol Hydrochloride) [package insert]","author":"Akrimax Pharmaceuticals, LLC"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000516845"},{"key":"e_1_2_9_13_1","volume-title":"Neurontin\u00ae (Gabapentin) [package insert]","author":"Pfizer, Inc."},{"key":"e_1_2_9_14_1","volume-title":"Lamictal\u00ae (Lamotrigine) [package insert]","author":"GlaxoSmithKline"},{"key":"e_1_2_9_15_1","volume-title":"Keppra\u00ae (Levetiracetam) [package insert]","author":"UCB, Inc."},{"key":"e_1_2_9_16_1","volume-title":"Zonegran\u00ae (Zonisamide) [package insert]","author":"Elan Pharma International Ltd."},{"key":"e_1_2_9_17_1","volume-title":"Botox\u00ae (OnabotulinumtoxinA) [package insert]","author":"Allergan Pharmaceuticals Ireland"},{"key":"e_1_2_9_18_1","volume-title":"Aimovig\u00ae (Erenumab\u2010aooe) [package insert]","year":"2021"},{"key":"e_1_2_9_19_1","volume-title":"Ajovi\u00ae (Fremanezumab\u2010vfrm) [package insert]","year":"2018"},{"key":"e_1_2_9_20_1","volume-title":"Emgality\u00ae (Galcanezumab\u2010gnlm) [package insert]","year":"2018"},{"key":"e_1_2_9_21_1","volume-title":"Vyepti\u00ae (Eptinezumab\u2010jjmr) [package insert]","year":"2020"},{"key":"e_1_2_9_22_1","volume-title":"Nurtec\u00ae ODT (Rimegepant) [package insert]","author":"AbbVie"},{"key":"e_1_2_9_23_1","volume-title":"Qulipta\u2122 (Atogepant) [package insert]","author":"AbbVie"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddstr.2006.11.003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1031-1_20"},{"issue":"1","key":"e_1_2_9_27_1","first-page":"87","article-title":"Deletions of genes encoding calcitonin\/alpha\u2010CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor\u2010like receptors in bone","volume":"6","author":"Lerner UH","year":"2006","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1530\/ror.0.0040081"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418821662"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa074"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2011.05.009"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.05.013"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04931-3"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420983292"},{"key":"e_1_2_9_35_1","volume-title":"European Medicines Agency: EMA\/CHMP\/413393\/2018 \u2010 Assessment report: Aimovig","year":"2018"},{"key":"e_1_2_9_36_1","volume-title":"European Medicines Agency: EMA\/118499\/2019\u2014Assessment report: Ajovy","year":"2019"},{"key":"e_1_2_9_37_1","volume-title":"European Medicines Agency: EMA\/708631\/2018\u2014Assessment report: Emgality","year":"2018"},{"key":"e_1_2_9_38_1","unstructured":"\u00a9 Copyright Lundbeck Seattle BioPharmaceuticals Inc. All Rights Reserved. Used with Permission. Data on file."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000054981.03589.E9"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00432.x"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(02)00563-5"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1481"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/985646"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0110"},{"key":"e_1_2_9_45_1","volume-title":"Aimovig\u00ae (Erenumab\u2010aooe) [approval letter] Drugs@FDA: FDA\u2010Approved Drugs"},{"key":"e_1_2_9_46_1","volume-title":"Ajovy\u00ae (Fremanezumab\u2010vfrm) [approval letter] Drugs@FDA: FDA\u2010Approved Drugs"},{"key":"e_1_2_9_47_1","volume-title":"Emgality\u00ae (Galcanezumab\u2010gnlm) [approval letter] Drugs@FDA: FDA\u2010Approved Drugs"},{"key":"e_1_2_9_48_1","volume-title":"Vyepti\u00ae (Eptinezumab\u2010jjmr) [approval letter] Drugs@FDA: FDA\u2010Approved Drugs"},{"key":"e_1_2_9_49_1","volume-title":"Nurtec ODT\u00ae (Rimegepant) [approval letter] Drugs@FDA: FDA\u2010Approved Drugs"},{"key":"e_1_2_9_50_1","volume-title":"Qulipta\u2122 (Atogepant) [approval letter] Drugs@FDA: FDA\u2010Approved Drugs"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14305","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:08:27Z","timestamp":1762078107000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/head.14305"],"URL":"https:\/\/doi.org\/10.1111\/head.14305","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"2021-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}